Motta I, Boeree M, Chesov D, Dheda K, Günther G, et al.
2023-07-21 • Clinical Microbiology and Infection
2023-07-21 • Clinical Microbiology and Infection
BACKGROUND Tuberculosis is a global health challenge and one of the leading causes of death worldwide. In the last decade, the tuberculosis treatment landscape has dramatically chang...
Global tuberculosis incidence has declined marginally over the past decade, and tuberculosis remains out of control in several parts of the world including Africa and Asia. Although tube...
Cox V, McKenna L, Acquah R, Reuter A, Wasserman S, et al.
2020-11-01 • International Journal of Tuberculosis and Lung Disease
2020-11-01 • International Journal of Tuberculosis and Lung Disease
Rapid diagnostics, newer drugs, repurposed medications, and shorter regimens have radically altered the landscape for treating rifampicin-resistant TB (RR-TB) and multidrug-resistant TB ...
Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JWC, Anderson LF, et al.
2018-09-08 • Lancet
2018-09-08 • Lancet
BACKGROUND Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed to estimate the association of treatment success and death with the use of individual drugs, ...
Migliori GB, Tiberi S, Zumla A, Petersen E, Chakaya JM, et al.
2020-02-01 • International Journal of Infectious Diseases
2020-02-01 • International Journal of Infectious Diseases
The continuous flow of new research articles on MDR-TB diagnosis, treatment, prevention and rehabilitation requires frequent update of existing guidelines. This review is aimed at provid...
Migliori GB, Marx FM, Ambrosino N, Zampogna E, Schaaf HS, et al.
2021-10-01 • International Journal of Tuberculosis and Lung Disease
2021-10-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND Increasing evidence suggests that post-TB lung disease (PTLD) causes significant morbidity and mortality. The aim of these clinical standards is to provide guidance on the...
Significant adverse events (AE) have been reported in patients receiving medications for multidrug- and extensively-drug-resistant tuberculosis (MDR-TB & XDR-TB). However, there is littl...
